scispace - formally typeset
J

J. David Spence

Researcher at Robarts Research Institute

Publications -  431
Citations -  20158

J. David Spence is an academic researcher from Robarts Research Institute. The author has contributed to research in topics: Stroke & Blood pressure. The author has an hindex of 67, co-authored 399 publications receiving 17671 citations. Previous affiliations of J. David Spence include University of Western Ontario & New York University.

Papers
More filters
Journal ArticleDOI

Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.

TL;DR: In this trial, moderate reduction of total homocysteine after nondisabling cerebral infarction had no effect on vascular outcomes during the 2 years of follow-up, and the consistent findings of an association of totalhomocysteines with vascular risk suggests that further exploration of the hypothesis is warranted and longer trials in different populations with elevated total homocrysteine may be necessary.
Journal ArticleDOI

Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke

TL;DR: Among patients with a PFO who had a cryptogenic stroke, the risk of subsequent ischemic stroke was lower among those assign to PFO closure combined with antiplatelet therapy than among those assigned to anti platelet therapy alone; however, PFOclosure was associated with higher rates of device complications and atrial fibrillation.
Journal ArticleDOI

Grapefruit juice–drug interactions

TL;DR: In vitro findings support the flavonoid, naringin, or the furanocoumarin, 6',7'-dihydroxybergamottin, as being active ingredients, but a recent investigation indicated that neither of these substances made a major contribution to grapefruit juice-drug interactions in humans.
Journal ArticleDOI

Carotid Plaque Area A Tool for Targeting and Evaluating Vascular Preventive Therapy

TL;DR: Carotid plaque area and progression of plaque identified high-risk patients and may improve cost-effectiveness of secondary preventive treatment and may be useful for targeting preventive therapy.